Medical products maker Cardinal Health Inc. would be allowed to resume production of pumps to control intravenous medication after fixing a problem that could have caused overdoses in the past, under a settlement with federal regulators the company announced Tuesday.

Over the last 12 years, there were 15 cases in which hospital patients could have received an overdose because of a sensitive keypad that programs how much medication the Alaris SE pump is to administer, Cardinal spokesman Troy Kirkpatrick said. Of the 15 cases, there were two injuries when the keypad recorded too much medicine.